Insights From Technical Analysis
NEXTDC (ASX: NXT): AI Demand Is Surging, but Earnings Must Catch Up Before the Next Leg Higher
NEXTDC (ASX: NXT) delivers strong revenue growth and record contracted utilisation, but heavy capex and negative statutory earnings cap near-term upside. AI-driven demand supports a justified premium, yet a sustained re-rating requires profitability acceleration and clearer cash-flow visibility.
Terra Metals (ASX: TM1) Rebounds 5% as Buyers Defend Key Support Zone.
Terra Metals (ASX: TM1) rebounded over 5% as buyers defended key support, while ongoing drilling success, expanding discoveries at the Dante Project, and a fully funded growth strategy continue to strengthen its position as a promising ASX critical minerals explorer.
BlueScope Steel (ASX: BSL) Breaks Higher as Investors Bet on Further Upside
BlueScope Steel shares have strengthened on improving earnings and investor confidence. The company is expanding production, upgrading facilities, and investing in low-emission steelmaking projects, positioning itself for long-term growth while maintaining exposure to global construction and infrastructure markets.
BPH Energy (ASX: BPH) Jumps 12.5% as Buyers Return to the Micro-Cap Explorer
BPH Energy shares surged 12.5% as investors focused on the upcoming PEP-11 court decision. The diversified micro-cap has exposure to gas exploration, hydrogen technology, and medical devices, with recent funding and project progress supporting renewed market interest.
Can Aristocrat Leisure (ASX: ALL) Extend Its Margin Expansion as Gaming Strength and Interactive Momentum Converge?
Aristocrat Leisure (ASX: ALL) delivers strong HY26 growth, expanding margins and cash generation across Gaming, Social Casino and iLottery, positioning the company for sustained earnings momentum and a multi year re rating. With NPATA up 8% (16% in constant currency), EBITDA up 6%, and segment profit expanding in constant currency, ALL has shown an expanding competitive advantage, strong cash generation, and a clear path to sustained NPATA growth.
Is Paradigm Biopharmaceuticals (ASX: PAR) Bottoming Out After Its Prolonged Downtrend?
Paradigm Biopharmaceuticals (ASX: PAR) is an Australian late-stage biotech developing injectable PPS, mainly for osteoarthritis. Its shares have fallen more than 95% since 2020 amid trial delays, dilution and losses, with August 2026 Phase 3 interim data now the key catalyst.